NEW YORK, February 6, 2017 /PRNewswire/ --
Pre-market, Stock-Callers.com focuses on the current performances of Sanofi(NYSE: SNY), Impax Laboratories Inc. (NASDAQ: IPXL), Heron Therapeutics Inc. (NASDAQ: HRTX), and Biostar Pharmaceuticals Inc. (NASDAQ: BSPM). These are major players in the Drug Manufacturers space which are engaged in the development and sale of medicines
Paris, France headquartered Sanofi's shares rose 0.30%, finishing last Friday's session at $40.63. A total volume of 746,745 shares was traded. Over the previous three months and since the start of this year, the stock has advanced 2.21% and 0.47%, respectively. The Company's shares are trading above their 50-day and 200-day moving averages by 1.16% and 1.66%, respectively. Additionally, shares of Sanofi, which researches, develops, manufactures, and markets various therapeutic solutions, have a Relative Strength Index (RSI) of 51.66.
On February 01st, 2017, Sanofi announced that the US Food and Drug Administration (FDA) approved Xyzal® Allergy 24HR as an over-the-counter (OTC) treatment for the relief of symptoms associated with seasonal and year-round allergies. Specifically, two formulations of Xyzal are now approved for OTC use - 5 mg tablets for ages 6 years and older, as well as 0.5 mg/mL oral solution for ages 2 years and older. Your complete research report on SNY can be retrieved for free at:
On Friday, shares in Hayward, California headquartered Impax Laboratories Inc. ended the session 1.48% higher at $13.70. The stock recorded a trading volume of 808,063 shares. The Company's shares have gained 3.40% on an YTD basis. The stock is trading above its 50-day moving average by 3.32%. Moreover, shares of Impax Labs, which develops, manufactures, and markets bioequivalent pharmaceutical products, have an RSI of 59.87.
On January 25th, 2017, Impax Labs announced that it will release its Q4 2016 and full year 2016 financial results on March 01st, 2017, prior to the open of the US financial markets. The Company will host a conference call and live webcast with the investment community at 8:30 a.m. ET on March 01st, 2017. A free report on IPXL is just a click away at:
Redwood City, California headquartered Heron Therapeutics Inc.'s stock climbed 2.22%, to close the day at $13.80 with a total trading volume of 460,839 shares. The Company's shares have advanced 5.34% since the start of this year. The stock is trading 0.73% below its 50-day moving average. Additionally, shares of Heron Therapeutics, which develops products to address unmet medical needs using its proprietary Biochronomer polymer-based drug delivery platform in the US, have an RSI of 53.91.
On January 31st, 2017, Heron Therapeutics announced that the underwriters for its recent public offering of common stock have exercised in full their option to purchase an additional 1,845,000 shares of its common stock. The Company stated that total net proceeds of the public offering, including the underwriters' option to purchase additional shares, are expected to be approximately $163.7 million, after deducting expenses and underwriting discounts and commissions. Sign up for your complimentary research report on HRTX at:
Shares in Xianyang, the People's Republic of China headquartered Biostar Pharmaceuticals Inc. recorded a trading volume of 25,995 shares. The stock ended at $2.83, down 2.41% from the last trading session. The Company's shares have gained 3.66% in the past month. The stock is trading below its 50-day moving average by 7.85%. Furthermore, shares of Biostar Pharma, which develops, manufactures, and markets over-the-counter and prescription pharmaceutical products for various diseases and conditions in the People's Republic of China, have an RSI of 46.26. Register for free on Stock-Callers.com and download the latest research report on BSPM at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: email@example.com Phone number: +44 330 808 3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA
Subscribe to our Free Newsletters!
Acute coronary syndrome (ACS) is a sudden, acute life-threatening condition caused by a dramatic ...
Sclerotherapy is a procedure used to treat spider veins, varicose veins and hemorrhoids by directly ...
HELLP syndrome is a rare but serious complication that affects pregnant women. If detected on time, ...View All